Be part of the knowledge.™
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Upcoming Events

Differentiating Biomarker-Driven First-Line Treatment Strategies in Metastatic Gastric/GEJ Cancers

Join our webinar with live Q&A to explore biomarkers, treatment strategies, and adverse effect management for metastatic gastric/GEJ adenocarcinoma.

Live Broadcast
0.75 available credits
Information
September 27, 2024
02:00 PM - 02:45 PM ET
ReachMD Healthcare Image
Details
Presenters
Related
Comments

  • Overview

    This CME webinar with live Q&A will provide an in-depth analysis of biomarker-driven strategies for the first-line treatment of metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma. Participants will learn to assess current and emerging biomarkers, analyze recent clinical trial data, and select optimal treatment regimens tailored to patient-specific characteristics. Additionally, the webinar will cover evidence-based approaches to monitor and manage adverse effects with the goal of improving treatment adherence and patient outcomes. This activity is designed to enhance the clinical decision-making process for healthcare professionals treating advanced gastric/GEJ cancers.

  • Disclosure of Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:  
    Nataliya Uboha, MD, PhD
    Faculty Leader, Early Phase Oncology Therapeutics Program
    Associate Professor, Department of Medicine
    University of Wisconsin
    Madison, WI

    Dr. Uboha has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research support: Ipsen, Arcus/Gilead, EMD Serono
    Consulting fees: STRATA oncology, BeiGene, Astellas, Astrazeneca, Gilead, Merck, Arcus, Pfizer, Eisai, Ipsen
    Ownership interest: Natera, Exact Science

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose   
    • Bing-E Xu, PhD, has nothing to disclose
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Assess current and emerging biomarkers to guide treatment decisions in patients with advanced gastric/gastroesophageal junction (GEJ) adenocarcinoma
    • Analyze recent clinical trial data on existing and investigational regimens for the first-line treatment of advanced gastric/GEJ adenocarcinoma
    • Select optimal first-line treatment strategies for patients with metastatic gastric/GEJ adenocarcinoma by incorporating treatment-specific and patient-related characteristics 
    • Implement evidence-based strategies to monitor and mitigate adverse effects of first-line treatment regimens for gastric/GEJ adenocarcinoma to optimize treatment adherence and outcomes

  • Target Audience

    This activity has been designed to meet the educational needs of medical oncologists and gastroenterologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with metastatic gastric/GEJ cancers. 

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     Global Learning Collaborative (GLC) designates this activity for 0.75 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.

     

     Global Learning Collaborative (GLC) designates this activity for 0.75 contact hours/0.075 CEUs of pharmacy contact hours.

    The Universal Activity Number for this program is JA0006235-0000-24-104-L01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)

     
    It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.

  • Commercial Support

    This activity is supported by independent educational grants from Astellas Pharma Global Development, Inc., Bristol Myers Squibb, and Merck Sharp & Dohme LLC.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This preseation is not intended to define an exclusive course of patient management; the participant should use his/her clinical  judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME, LLC you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

Details
Presenters
Related
Comments
Recommended

  • Overview

    This CME webinar with live Q&A will provide an in-depth analysis of biomarker-driven strategies for the first-line treatment of metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma. Participants will learn to assess current and emerging biomarkers, analyze recent clinical trial data, and select optimal treatment regimens tailored to patient-specific characteristics. Additionally, the webinar will cover evidence-based approaches to monitor and manage adverse effects with the goal of improving treatment adherence and patient outcomes. This activity is designed to enhance the clinical decision-making process for healthcare professionals treating advanced gastric/GEJ cancers.

  • Disclosure of Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:  
    Nataliya Uboha, MD, PhD
    Faculty Leader, Early Phase Oncology Therapeutics Program
    Associate Professor, Department of Medicine
    University of Wisconsin
    Madison, WI

    Dr. Uboha has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research support: Ipsen, Arcus/Gilead, EMD Serono
    Consulting fees: STRATA oncology, BeiGene, Astellas, Astrazeneca, Gilead, Merck, Arcus, Pfizer, Eisai, Ipsen
    Ownership interest: Natera, Exact Science

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose   
    • Bing-E Xu, PhD, has nothing to disclose
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Assess current and emerging biomarkers to guide treatment decisions in patients with advanced gastric/gastroesophageal junction (GEJ) adenocarcinoma
    • Analyze recent clinical trial data on existing and investigational regimens for the first-line treatment of advanced gastric/GEJ adenocarcinoma
    • Select optimal first-line treatment strategies for patients with metastatic gastric/GEJ adenocarcinoma by incorporating treatment-specific and patient-related characteristics 
    • Implement evidence-based strategies to monitor and mitigate adverse effects of first-line treatment regimens for gastric/GEJ adenocarcinoma to optimize treatment adherence and outcomes

  • Target Audience

    This activity has been designed to meet the educational needs of medical oncologists and gastroenterologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with metastatic gastric/GEJ cancers. 

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     Global Learning Collaborative (GLC) designates this activity for 0.75 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.

     

     Global Learning Collaborative (GLC) designates this activity for 0.75 contact hours/0.075 CEUs of pharmacy contact hours.

    The Universal Activity Number for this program is JA0006235-0000-24-104-L01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)

     
    It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.

  • Commercial Support

    This activity is supported by independent educational grants from Astellas Pharma Global Development, Inc., Bristol Myers Squibb, and Merck Sharp & Dohme LLC.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This preseation is not intended to define an exclusive course of patient management; the participant should use his/her clinical  judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME, LLC you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

Recommended

Schedule13 Dec 2024
PrevNext

Program Chapters

Segment Chapters

Playlist:

Recommended